Found 6 matching trials
Safety and Tolerability Study of 2 Dose Level of Arikayce™ in Patients With Bronchiectasis and Chronic Infection Due to Pseudomonas Aeruginosa. PHASE2 This is a study to determine the safety and tolerability of 28 days of dail...
Show More Location
Multiple Locations
Learn More & Join Trial
Safety/Tolerability Study of Arikayce™ in Cystic Fibrosis Patients With Chronic Infection Due to Pseudomonas Aeruginosa PHASE1 This is a study to determine the safety and tolerability of 28 days of dail...
Show More Location
Multiple Locations
Learn More & Join Trial
Study to Evaluate Arikace™ in CF Patients With Chronic Infection Due to Pseudomonas Aeruginosa PHASE3 A major factor in the respiratory health of Cystic Fibrosis (CF) subjects i...
Show More Location
Multiple Locations
Learn More & Join Trial
Study to Evaluate ALIS (Amikacin Liposome Inhalation Suspension) in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium Complex PHASE3 The main objective of this study is to evaluate the efficacy of ALIS (amika...
Show More Learn More & Join Trial
Liposomal Amikacin for Inhalation (LAI) for Nontuberculous Mycobacteria PHASE2 The purpose of this study is to evaluate the efficacy, safety and tolerabil...
Show More Location
Multiple Locations
Learn More & Join Trial
Multidose Safety and Tolerability Study of Dose Escalation of Liposomal Amikacin for Inhalation (ARIKACE™) PHASE1 A major factor in the respiratory health of cystic fibrosis (CF) subjects i...
Show More Location
Multiple Locations
Learn More & Join Trial